Q-omics provides the consensus-scored NBPF12 profile across patient tissues and cancer cell-line models. NBPF12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NBPF12 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, NBPF12 RNA expression shows 21,747 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where NBPF12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBPF12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBPF12 survival associations across molecular data types. NBPF12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBPF12 RNA expression–survival associations across cancer types. High NBPF12 expression shows unfavorable associations in ACC and KICH, but favorable associations in HNSC, SKCM, PAAD and READ. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for NBPF12 RNA expression.
This table summarizes NBPF12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NBPF12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBPF12 shows lower tumor expression in THCA, KICH, BRCA, LUAD and LUSC and higher tumor expression in HNSC. The THCA box plot shows higher NBPF12 RNA expression in normal versus tumor tissue (log2 FC = −0.638, t-test p < 0.001).
This table shows molecular features associated with NBPF12 in patient tissues and cancer cell lines. In patient samples, NBPF12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NBPF12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
